Company Legal Name
Latest Valuation
Founded Year
Headquarter
Eikon Therapeutics operates a drug discovery platform that combines live-cell protein tracking technology with advanced data science to develop treatments for serious diseases. Founded in 2019 and headquartered in Hayward, California, the company differentiates itself through its proprietary approach to observing protein behavior in living cells, providing unprecedented insights into disease mechanisms. This innovative methodology enables more precise identification of therapeutic targets and drug candidates compared to traditional discovery methods. The company focuses on leveraging its unique technological capabilities to advance a pipeline of potential treatments addressing significant unmet medical needs in various therapeutic areas.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
